PREVALENCE SURVEY OF PLASMODIUM FALCIPARUM ANTIMALARIAL DRUG RESISTANCE MARKERS AT SITES IN INDIA
- Conditions
- Malaria disease
- Registration Number
- TCTR20171128005
- Lead Sponsor
- St. John Research Institute
- Brief Summary
The results indicate that artesunate + sulphadoxine-pyrimethamine, the artemisinin-based combination therapy (ACT) used as the first-line antimalarial treatment, is likely to be efficacious. However, there appears to be a high prevalence of the molecular markers seen in recrudescent parasites following treatment with lumefantrine. These results will be completed with testing for additional mutations in pfmdr1 and pfcrt genes known to be associated with such recrudescence.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 400
Participants must meet all of the inclusion criteria to participate in the study.
-Patients (6 months - 75 years) with confirmed uncomplicated P. falciparum infection
-Written informed consent obtained
All participants meeting inclusion criteria will have their dried blood spots retained for parasite molecular analyses.
Patients presenting signs of severe malaria will be excluded from the survey to prevent any delay in the management of the patient.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Prevalence and geospatial trends of Molecular markers 1 year Surveillance
- Secondary Outcome Measures
Name Time Method Visualization and dissemination of molecular marker prevalence data to inform public health official 1 year Mapping